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A B S T R A C T
Two new tridesmosidic cycloartane-type triterpene glycosides (1 and 2) were isolated from the methanolic
extract of the roots of Astragalus brachycalyx FISCHER (A. brachycalyx) along with ten (3–12) known cycloartane-
type triterpene glycosides. Structures of the new compounds were established as 3-O-β-D-xylopyranosyl-6-O-β-D-
glucopyranosyl-16-O-β-D-glucopyranosyl-3β,6α,16β,24(S)-25-pentahydroxycycloartane (1), 3-O-[α-L-arabino-
pyranosyl-(1→2)-β-D-xylopyranosyl]-6-O-β-D-glucopyranosyl-16-O-β-D-glucopyranosyl-3β,6α,16β,24(S)-25-pen-
tahydroxycycloartane (2), by using 1D and 2D-NMR techniques and mass spectrometry.
In vitro immunomodulatory effects and hemolytic activities of the new saponins (1 and 2) and acetylated form
of 1 (1a) were studied together with the BuOH and MeOH extracts of Astragalus brachycalyx. The results have
proven that tridesmosidic Astragalus cycloartanes are noteworthy immunomodulatory compounds via induction
of cytokine production, namely IL-2 and IFN-γ. The test compounds also resulted slight hemolysis at very high
doses substantiating a safer profile compared to the positive control QS-21.
1. Introduction
The genus Astragalus L., belonging to the family of Fabaceae with
more than 3.000 species of herbs and small shrubs, is broadly dis-
tributed in Mountainous areas throughout the world, mostly in Asia.
Iran alone, being the richest center of Astragalus habitation, shelters
more than 850 species, 527 of which are endemic in the flora of Iran
(Ranjbar and Karamian, 2002; Massoumi 1998). The crude drugs pre-
pared from Astragalus roots are used for treating some illnesses such as
leukemia, respiratory infections and diabetes in Iranian folk medicine.
The phytochemical studies performed on Astragalus species mainly re-
sulted in the isolation of a series of oleanane- and cycloartane-type
triterpene glycosides (Bedir et al., 1998, 1999; Gülcemal et al., 2011;
Horo et al., 2010; Polat et al., 2010; Savran et al., 2012). Some
bioactive compounds from Astragalus species are reported to contain
anticancer and immunostimulatory activities (Rios and Waterman,
1997; Bedir et al., 2000). Li (2000) showed that polysaccharides from
Astragalus mongholicus, consisting of glucose and arabinose moieties,
increase not only the synthesis of RNA, DNA and protein but also the
specific antibody formation in mouse spleen. To discover the con-
tributory role of immunomodulatory effects of saponins, the
lymphocyte stimulation test was performed on eight cycloartane-type
saponins isolated from Astragalus melanophrurius (Calis et al., 1997). It
was shown that the higher concentrations of the test compounds
(100–200 μg/mL) had inhibitory effect on thymidine incorporation. In
another study, the effects of nineteen cycloartane-type triterpene gly-
cosides, isolated from Astragalus species, were investigated on macro-
phage activation utilizing a transcription factor-based bioassay for the
activation of Nuclear Factor Kappa B (NF-κB) in a human macrophage/
monocyte cell line. The only compound exhibiting activity was as-
tragaloside I, increased NF-κB-directed luciferase expression up to 65%.
It also increased the mRNA expression of inflammatory cytokines, such
as IL-1β and TNF-α (Bedir et al., 2000). Verotta et al. (2001) reported
the results of their study based on the effect of cycloartane saponins
obtained from Astragalus peregrinus as modulators of lymphocyte pro-
liferation. The compounds showed stimulation in proliferation of mouse
splenocytes, and were not cytotoxic. IL-2, a cytokine produced by ac-
tivated T cells, is proven to be a powerful immunostimulatory and
antineoplastic agent. Yesilada et al. (2005) reported that astragaloside
VII (AST VII), a tridesmosidic glycoside of cycloastragenol, was the
most remarkable compound in regards to induction of IL-2 production
(%139.6). In a continuation study, Nalbantsoy et al. (2011) evaluated
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adjuvant and hemolytic effects of IL-2 stimulating Astragalus com-
pounds. AST VII and Macrophyllosaponin B (MAC B) generated im-
portant specific antibody and cellular response against BSA in mice, and
both compounds were proposed to be potent immunoregulatory agents
to be used in vaccine formulations as adjuvants. In the case of hemo-
lysis, AST VII showed very low (0.54%) hemolytic index at the highest
treatment concentration of 500 μg/mL (Nalbantsoy et al., 2012).
Although Iran inhabitates many endemic Astragalus species, there is
no detailed phytochemical study reported on Iranian Astragalus plants.
Here we reported the isolation and structure elucidation of two new
cycloartane-type triterpene glycosides (1-2) along with ten known cy-
cloartane-type triterpene glycosides (3-12) from the methanolic extract
of A. brachycalyx, an Iran-Turan endemic. Additionally, the methanol
and butanol extracts of A. brachycalyx, and the new saponins (1 and 2)
together with 1a were evaluated for in vitro cytokine release (IL-2, IL-
17A and IFN-γ) from human whole blood using ELISA. Apart from this,
hemolytic activities of the same samples were studied in human red
blood cells.
2. Results and discussion
The molecular formula of 1 was determined as C47H80O19 from
HRESIMS (m/z 987.4962 [M+ K]+) and the 1H and 13C NMR data.
The 1H NMR spectrum of 1 showed signals due to a cyclopropane
methylene at δ 0.49 and 0.19 (each 1H, d, J= 3.9 Hz), six tertiary
methyl groups at δ 2.07, 1.52 (6H), 1.39, 1.22, 0.88, a secondary me-
thyl group at δ 1.00 (d, 6.5) and four methine proton signals at δ 4.39
(m), 3.97 (m), 3.70 (m) and 3.53 (dd, J= 11.6, 4.3 Hz), which were
indicative of secondary alcoholic functions. The NMR data of the
aglycone moiety of 1 were in good agreement with those reported for
cyclocanthogenin (Bedir et al., 1998) with glycosidation shifts for C-3
(δ 88.5), C-6 (δ 79.9) and C-16 (δ 82.4). Furthermore, the 1H NMR
spectrum of 1 clearly showed three anomeric proton doublets at δ 4.89
(d, J= 7.7 Hz), 4.85 (d, J= 7.5 Hz) and 4.73 (d, J= 7.7 Hz) in the
downfield region, indicative of three β-linked sugar units. These cor-
related to C-atom signals at δ 105.1, 107.4 and 106.3, respectively, in
the HSQC spectrum.
The HMQC, HMBC and COSY data led to identify these sugar units
as one β-xylopyranosyl and two β-glucopyranosyl units, all of which
were also suggested to have a D-configuration based on the biogenetic
considerations derived from Astragalus cycloartanes (Bedir et al., 1998,
1999; Calis et al., 1997; Gülcemal et al., 2011; Horo et al., 2010; Polat
et al., 2010; Savran et al., 2012) and the optical rotation data of each
isolated sugar.
The HMBC correlations between the proton signal at δ 4.85 (H-1xyl)
and the carbon resonance at δ 88.5 (C-3), the proton signal at δ 4.89 (H-
1glcI) and the carbon resonance at δ 79.9 (C-6) and the proton signal at δ
4.73 (H-1glcII) and the carbon resonance at δ 82.4 (C-16) allowed us to
determine the linkage site of the sugar units. Thus, the new compound 1
was elucidated as 3-O-β-D-xylopyranosyl-6-O-β-D-glucopyranosyl-16-O-
β-D-glucopyranosyl-3β,6α,16β,24(S)-25 pentahydroxycycloartane.
The HRESIMS data of 2 indicated a molecular formula of C52H88O23
(m/z 1103.5646 calcd.) that was deduced from the ion peak at m/z
1103.5648 (C52H88O23Na). The 1H NMR and 13C chemical shifts of the
aglycone moiety of 2 were superimposable with those of 1. Moreover,
for the sugar portion of 2 in comparison with that of 1, the occurrence
of an additional sugar unit was observed. The 1H NMR showed signals
for four anomeric protons at δ 5.22 (d, J= 6.6 Hz), 4.91 (d,
J= 7.7 Hz), 4.86 (d, J= 6.8 Hz) and 4.75 (d, J= 7.6 Hz), which
showed correlations in the HSQC spectrum with the anomeric carbon
signals at δ 106.7, 105.4, 105.4 and 106.6, respectively. These data, in
combination with HSQC, HMBC, COSY correlations, showed that 2
differed from 1 only by the presence of an additional α-arabinopyr-
anosyl unit. Therefore, on the basis of the HMBC correlation between
the proton signal at δ 5.22 (H-1ara) and the carbon resonance at δ 83.5
(C-2xyl) the arabinose was located at C-2xyl. The D configuration of
xylose and glucose and L configuration of arabinose units were estab-
lished after hydrolysis of saponin fraction P of A. brachycalyx and
confirmation by the optical rotation data of each isolated sugar.
Consequently, compound 2 was identified as 3-O-[α-L-arabinopyr-
anosyl-(1→ 2)-β-D-xylopyranosyl]-6-O-β-D-glucopyranosyl-16-O-β-D-
glucopyranosyl-3β,6α,16β,24(S)-25-pentahydroxycycloartane.
Additionally, one known cycloartane-type triterpene, cycloas-
tragenol (3) (Bedir et al., 1999) and nine known cycloartane-type tri-
terpene glycosides, Astragaloside IV (4) (Kitagawa et al., 1983a), cy-
clocanthoside E (5) (Isaev et al., 1992), astragaloside VIII (6) (Kitawaga
et al., 1983b), 3-O-β-D-xylopyranosyl-6,25-di-O-β-D-glucopyranosyl-
3β,6α,16β,24(S),25-pentahydroxycycloartane (7) (Gülcemal et al.,
2011) cyclocephaloside I (8) (Bedir et al., 1998), astrachrysoside A (9)
(Gan et al., 1986), cycloaraloside D (10) (Isaev, 1991), oleifolioside A
(11) and oleifolioside B (12) (Ozipek et al., 2005) were isolated.
IL-2, with a critical role in the immune system by assisting immature
T cells to differentiate into regulatory T cells, effector T cells or memory
T cells, helps the body to fight against infectious diseases directly or
indirectly (Liao et al., 2011). IFNγ, known as type II interferon, is an-
other vital cytokine with immunostimulatory potential. It has been
confirmed that IFNγ can play a crucial role in immune response against
some intracellular pathogens in diseases such as Chagas, and it co-
ordinates a dissimilar array of cellular programs through transcriptional
regulation of genes that are immunologically relevant (Ben-Asouli
et al., 2002; Schroder et al., 2004). One of the most important prop-
erties of IFNγ is on the innate and adaptive immune response against
tumors and pathogens (Lin and Young, 2013). IL-17A, originally iden-
tified as a transcript from a rodent T-cell hybridoma by Rouvier et al.
(1993), is the chief member of the family named IL-17A cytokine group,
and one of its essential roles is induction and facilitation of pro-in-
flammatory responses (Aggarwal and Gurney, 2002). IL-17A inhibitors
are under investigation to treat autoimmune diseases like rheumatoid
arthritis, psoriasis and inflammatory bowel disease. This group of cy-
tokine inhibitors can lead to an aberrant airway neutrophil response to
allergen stimuli (Yang et al., 2008). The role of IL-17A for Th17 cells in
vitiligo pathogenesis treatment has also been confirmed (Zhou et al.,
2015). Concisely, IL-2, IFNγ and IL-17A are essential cytokines with
different functions for the immune system, and developing new mole-
cules modulating them will have a potential use in therapy.
Previous studies suggest that the specific molecules turning on the
cytokine gene expression is more beneficial than injectable therapeutic
doses of cytokines signifying the importance of the discovery of potent
immunostimulatory agents (Gillis and Williams, 1998; Oda et al., 2003;
Pandey et al., 2016; Hu et al., 2016).
Astragalus derived preparations are known for their stimulatory ef-
fects on cellular and humoral immune responses. Previous studies un-
doubtedly pointed to induction of cytokines such as interleukins and
interferons for their immunostimulatory actions (Yang et al., 2005;
Nalbantsoy et al., 2011, 2012). Not only crude Astragalus preparations
but also its purified polysaccharides and saponins were demonstrated
immunomodulatory activity in line with previous studies (Behboudi
et al., 1999; Yang et al., 2008; Nalbantsoy et al., 2012; Lai et al., 2014).
Thus Astragalus species and their components deserve detailed in-
vestigation for their immunomodulatory properties.
In this study, the effects of two newly established cycloartane-type
saponins (compounds 1 and 2) along with compound 1a (acetylated
form of compound 1), methanol and butanol extracts of A. brachycalyx
were studied on the human whole blood stimulated with PMA plus
ionomycin for IL-2, IFN-γ and IL-17A cytokines’ release at 3 and 6 μg
concentrations, (Fig. 3). AST VII and QS-21 saponins were used as po-
sitive controls. At 3 μg concentration, AST VII increased the level of IL-2
(1263.2 ± 0.89 pg/mL ( × 30), P < 0.001) whereas it did not show
any effect on IFN-γ (283.6 ± 0.12 pg/mL ( × 20), P > 0.05) and IL-
17A (783.7 ± 0.04 pg/mL ( × 20), P > 0.05) production. However,
AST VII increased the concentration of IL-2 (1217.65 ± 0.03 pg/mL
( × 30), P < 0.001) and IL-17A (317.66 ± 0.32 pg/mL ( × 20),
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P < 0.05) at 6 μg with no effect on IFN-γ production
(823.67 ± 0.19 pg/mL ( × 20), P > 0.05). QS-21 exhibited sub-
stantial effect on IFN-γ (395.85 ± 0.32 pg/mL, P < 0.001) and IL-2
(1217.02 ± 1.07 pg/mL ( × 30), P < 0.01) release at 3 μg con-
centration. Besides, QS-21 exhibited more potency towards IL-2 and
IFN-γ stimulation (1416.94 ± 0.41( × 30) and 399.20 ± 0.29
( × 20), pg/mL, respectively) (P < 0.001) at 6 μg concentration,
whereas it did not show any effect on IL-17A concentration.
The results showed that the concentration of IL-2 was significantly
increased by 1 (6 μg), 2 (6 μg), the MeOH extract (6 μg) and slightly
with 1a (3 μg) compared to the control group (P< 0.01, P< 0.001 or
P<0.05). The IFN-γ concentration was stimulated considerably at 3 μg
dose of compound 2 (390.33 ± 0.02 pg/mL ( × 20), P< 0.001)
possessing tridesmosidic framework with 4 sugar moieties compared to
those of 1 and 1a with trisaccharidic nature (P< 0.01 or P< 0.001).
The MeOH extract showed a slight effect on IFN-γ induction at 6 μg
(P<0.05). Moreover, the concentration of IL-17A was not effected by
any of the tested molecules (P>0.05) in comparison to the control
group.
Administraton of 1a, the fully acetylated form of 1, resulted in al-
tered levels of cytokine release compared to 1 at 3 and 6 μg con-
centrations. Compound 1a showed slightly higher IL-2 induction
(1165.48 ± 0.08 pg/mL ( × 30), P < 0.05) than compound 1
(1136.47 ± 0.01 pg/mL ( × 30), P > 0.05) at 3 μg, whereas 1
(1168.56 ± 0.04 pg/mL ( × 30), P < 0.05) increased the level of IL-2
in comparison to 1a (1116.84 ± 0.2 pg/mL ( × 30), P > 0.05) at
6 μg concentration (Fig. 3). These results imply that more hydrophobic
forms of tridesmosidic Astragalus saponins still put forth IL-2 induction
at lower doses (3 μg) signifying their potential use in oil based adjuvant
systems. In modern vaccines, oil-in-water (o/w) emulsions are used as
adjuvants safely and successfully. The most remarkable o/w emulsions
used clinically are MF59 and AS03. Both adjuvant systems include
squalene at ∼2.5% (v/v) in the final vaccine formulation (Fox, 2009).
Basically, the immune response is categorized in two groups based
on the cytokine profile induced: Th1 or Th2. The Th1 profile is char-
acterized by the initial production of IFNγ and IL-12 with an effector
phase of T lymphocytes producing IL-2 and IFNγ and mediating cyto-
toxic activity (CTL). In contrast, Th2 responses are influenced by IL-4
with predominantly IL-5 and IL-10 producing T cells in the effector
phase that drive antibody production (Nalbantsoy et al., 2011, 2012,
Yang et. al., 2005). In this paper, the presented saponins were found
predominantly effective on Th1 as associated with induction of IL-2 and
IFNγ. Hu et al. (2016) tested the role of 5 different saponins on altering
levels of IL-4, IL-10, IL-2, and IFN-γ. Their results revealed increments
in IFN-γ concentrations together with upregulation of IL-2 expression,
validating our immunomodulatory findings.
Saponins cause hemolysis because of their well-known effects: cell
membrane swelling due to pore formation, partial entry of extracellular
Ca2+ and ceramide formation (Bissinger et al., 2014). In this study,
Astragalus brachycalyx extracts and isolates were also investigated for
their hemolytic activities to prove that observed immunostimulatory
activities are not originating from such action. As shown in Table 3, QS-
21 showed a notably strong hemolytic activity in all tested concentra-
tion (5000, 500, 250, 125, 50 μg/mL (P < 0.01) and 25, 12.5, 2.5 μg/
mL (P < 0.05). Moreover, AST VII exhibited slight hemolysis for
5000 μg/mL concentration (P < 0.05), while there was no hemolytic
activity for the doses of 250, 125, 50, 25, 12.5 and 2.5 μg/mL
(P > 0.05). As it is shown in Fig. 1, acetylated derivative 1a (500 μg/
mL) demonstrated a slight hemolytic activity (P < 0.05), whereas 1
did not cause any hemolysis at all tested concentrations. According to
the above mentioned results, one could state that the tridesmosidic
saponins of Astragalus genus are safer adjuvant candidates compared to
the well-investigated QS-21 that is a strong hemolytic agent.
Consequently, our findings surely warrant further studies especially
focusing on the mechanism of action and in vivo potential of the de-
scribed saponins.
3. Experimental
3.1. General
Optical rotations were measured on a JASCO DIP 1000 polarimeter.
The 1H, 13C NMR spectra as well as 2D-NMR experiments (COSY, HSQC
and HMBC) were obtained using 400 MHz for 1H NMR. 100 MHz for
13C NMR were measured on a Varian AS 400 Mercury spectrometer for
compound 1a and compound 2, and standard Bruker program on a
UltraShield Plus 500 MHz (Bruker) (NMR Unite at the College of
Pharmacy, Prince Sattam bin Abdulaziz University) spectrometer op-
erating at 500 MHz for proton and 125 MHz for carbon for compound
1. The chemical shift values are reported in δ (ppm) relative to the
residual solvent peak, and the coupling constants (J) are reported in
Hertz (Hz) and MS spectra were measured on a LC/MS High resolution
Time of Flight (TOF) Agilent 1200/6530 instrument; CC, silica gel 60
(Merck); GPC (General Permeation Chromatography, Sephadex LH-20).
All 2DNMR spectra were acquired in Pyridine-d5 (99.50%,
SigmaAldrich) standard pulse sequences and phase cycling were used
for COSY, HSQC and HMBC spectra.
3.2. Plant material
The root and stem parts of Astragalus brachycalyx FISCHER was
collected from Sardasht City, Landi Sheykhan Mountain, altitude of
2400 m, West Azerbaijan Province, Iran, in August 2013, and identified
by Dr. Ali-Asghar Massoumi (botanist) in Research Institute of Forests
and Rangelands. A voucher specimen (Tehran 19536) was deposited at
Herbarium Research and The Application Center in Research Institute
of Forests and Rangelands, Tehran, Iran.
3.3. Extraction and isolation
Air-dried and powdered roots of A. brachycalyx (900 g) was ex-
tracted with MeOH (3 × 2.5 L) for 5 days under reflux. After filtration,
the solvent was removed by rotary evaporation affording a crude ex-
tract of 98 g. The extract was dissolved in water (700 mL) and succes-
sively partitioned with n-hexane (4 × 300 mL), CH2Cl2 (4 × 300 mL),
EtOAc (4 × 300 mL), and n-BuOH (4 × 300 mL). After evaporation the
n-BuOH extract (20.71 g) was applied to Vacuum Liquid
Chromatography (VLC) using reversed-phase silica (Lichroprep RP-18,
25–40 μm, 600 g) employing H2O-MeOH (90:10; 80:20; 60:40; 50:50;
40:60; 20:80) and MeOH to give 23 main fractions (Fr. A-W). Fraction
M (5.61 g) was applied to an open column chromatography using
normal-phase silica gel (23 × 1200 mm, 600 g) as stationary phase.
The column was started and continued with CHCl3-MeOH-H2O mix-
tures (90:10:1; 85:15:1.5; 80:20:2; 75:25:2.5; 70:30:3; 61:32:7;
64:50:10) to provide 3259 fractions. Fractions M-800-970 (56 mg) were
combined and fractionated over reversed-phase material (Lichroprep
RP-18, 25–40 μm, 20 × 130 mm, 15 g) eluting with MeOH-H2O
(50:50) mixture to afford compounds 3 (8.4 mg) and 4 (11 mg).
Fractions M-1200-1450 (379.9 mg) were combined and further sepa-
rated over normal phase silica gel (23 × 450 mm, 60.6 g) using a step-
gradient of EtOAc-MeOH-H2O (100:10:5; 100:15:7.5; 100:17.5:13.5;
100:20:15; 100:25:20) to give 489 subfractions. Subfractions 130–168
(38.1 mg) were combined and subjected to column chromatography by
using reversed-phase material (Lichroprep RP-18, 25–40 μm,
20 × 100 mm, 10.3 g) and isocratic MeOHeH2O mobile phase system
(5:5) to give 5 (9.5 mg). Subfractions 171–179 (25 mg) were combined
and chromatographed over normal phase silica gel (23 × 450 mm,
70 g) employing with CHCl3-MeOH-H2O (90:10:1; 80:20:1; 80:20:2;
70:30:3; 61:32:7) mixtures and methanol to afford compounds 2
(18 mg) and 6 (4.4 mg). Subfractions 279–302 (90 mg) were combined
and subjected to column chromatography by using normal-phase silica
gel (20 × 260 mm, 22.2 g) eluting with CHCl3-MeOH-H2O solvent
system (85:15:1.5; 80:20:2; 75:25:2.5; 70:30:3; 61:32:7; 64:50:10) to
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yield a mixture including two compounds (80 mg). As the open column
chromatography was not successful to separate these two metabolites
due to their almost identical polarity, the mixture was acetylated using
acetic anhydride and pyridine. Prior to acetylation, the mixture was
analyzed by 1H-NMR to make sure that no acetyl group was present for
both compounds. After acetylation, the mixture was applied to column
chromatography by using normal-phase silica gel (20 × 260 mm,
22.2 g) eluting with CHCl3- CH3COCH3 (80:20; 70:30; 60:40; 50:50;
40:60) to yield 1a (65 mg) and 7a (5 mg). Compounds 1a and 7a were
hydrolyzed with 0.5 N NaOH. After neutralization, reaction mixtures
were applied to silica gel column (30 × 1000 mm, 48 g) with the sol-
vent system CHCl3-CH3COCH3 (60:40; 50:50; 40:60; 30:70) affording 1
(48 mg) and 7 (2.5 mg). The spectra and spectral data of 1a were
provided to support structural determination of 1 (see Supplementary
file). Fractions M-2687-2900 (1.0 g) were combined and rechromato-
graphed over an open column chromatography using silica gel
(35 × 120 mm, 350 g) as stationary phase. Elution was performed with
CHCl3-MeOH-H2O (90:10:1; 80:20:1; 80:20:2; 70:30:3; 61:32:7) to give
compounds 8 (25.5 mg) and 9 (40.8 mg). The main fraction O (2.70 g)
was fractionated over a silica gel column (30 × 1000 mm, 390 g).
Elution was carried out with CHCl3-MeOH-H2O (85:15:1.5; 80:20:2;
75:25:2.5; 70:30:3) to yield 1110 fractions. Fractions O-90-110
(307 mg) were subjected to column chromatography by using normal-
phase silica gel (35 × 120 mm, 150 g) eluting with CHCl3-MeOH-H2O
solvent system (90:10:1; 80:20:2; 70:30:3; 61:32:7) to yield 10 (40.3).
Fractions O-138-210 (100 mg) were applied to silica gel column
(35 × 120 mm, 50 g) with the solvent system CHCl3-MeOH-H2O
(90:10:1; 80:20:2; 70:30:3; 61:32:7) yielding 11 (9.2). Fractions N-900-
943 (107 mg) were subjected to column chromatography by using
normal-phase silica gel (35 × 120 mm, 55 g) eluting with CHCl3-
MeOH-H2O solvent system (90:10:1; 80:20:2; 70:30:3; 61:32:7) to yield
12 (6.2).
3.3.1. 3-O-β-D-xylopyranosyl-6,16-di-O-β-D-glucopyranosyl-
3β,6α,16β,24(S)-25 pentahydroxycycloartane (1)
Amorphous white solid; C47H80O19; [α]19D + 14.6 (c 0.1 MeOH); IR
ν KBrmax cm−1: 3435 ( >OH), 2930 ( >CH); for 1H and 13C NMR
(Pyridine-d5, 500 MHz) data of the aglycone moiety and the sugar
portion see Tables 1 and 2, respectively; HRESIMS m/z 987.4962 [M
+ K]+ (calcd. for C47H80O19K, 987.4960) (positive mode).
3.3.2. 3-O-β-D-xylopyranosyl-6,16-di-O-β-D-glucopyranosyl-
3β,6α,16β,24(S)-25 pentahydroxycycloartane dodecaacetate (1a)
Amorphous white solid; C73H106O32; [α]23D + 5.0 (c 0.2 MeOH); IR
ν KBrmax cm−1: 3435 ( >OH), 2930 ( >CH), 1680 (C]O); for 1H and
13C NMR (CDCl3, 400 MHz) data of the aglycone moiety and the sugar
portion see Tables 1 and 2, respectively; HRESIMS m/z 1533.6456 [M
+ K]+ (calcd. For C73H106O32 K 1533.6454) (positive mode).
Fig. 1. Structures of compounds 1, 1a and 2.
Table 1
13C and 1H NMR data (J in Hz) of the aglycone moieties of 1 and 2 (400 MHz for 2, and
500 MHz for 1, δ ppm, in Pyridine-d5).
C/H 1 2
δC δH (J in Hz) δC δH (J in Hz)
1 32.1 1.58, m; 1.23, m 32.4 1.61, m; 1.31, m
2 30.0 2.36, m; 1.96, m 30.2 2.29, m; 1.96, m
3 88.5 3.53, dd (11.6, 4.3) 88.1 3.48, dd (11.4, 4.0)
4 42.4 – 42.8 –
5 52.3 1.90, d (9.1) 52.5 1.90, d (8.0)
6 79.9 3.70, m 79.4 3.74, m
7 34.6 2.36, m; 1.75, m 34.6 2.31, m; 1.87, m
8 46.2 1.76, m 45.5 1.83, m
9 21.0 – 21.5 –
10 28.5 – 28.7 –
11 26.0 1.84, m; 1.30, m 26.3 1.85, m; 1.30, m
12 34.2 2.36 (2H), m 33.0 2.29 (2H), m
13 45.5 – 45.9 –
14 46.7 – 47.0 –
15 47.3 2.44, dd (13.7, 8.0); 2.11, m 47.4 2.46, dd (13.9, 7,5); 2.13, m
16 82.4 4.39, m 82.6 4.43, dd (6.8, 1.6)
17 57.2 1.87, m 57.6 1.91, m
18 18.8 1.22, s 18.8 1.25, s
19 29.1 0.49, d (3.9)
0.19, d (3.9)
28.5 0.55, d (4.0)
0.22, d (4.0)
20 29.4 2.36, m 29.8 2.40, m
21 17.4 1.00, d (6.5) 17.7 1.04, d (6.4)
22 33.4 2.26 m; 1.62, m 33.7 2.28, m; 1.64, m
23 28.6 2.06 m; 1.83, m 29.0 2.13 m; 1.88, m
24 77.8 3.97, m 78.3 3.98, m
25 72.8 – 72.9 –
26 25.8 1.52, s 26.0 1.54, s
27 25.8 1.52, s 26.0 1.54, s
28 28.5 2.07, s 28.3 1.94, s
29 16.4 1.39, s 17.7 1.38, s
30 19.9 0.88, s 20.0 0.97, s
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3.3.3. 3-O-[α-L-arabinopyranosyl-(1→ 2)-β-D-xylopyranosyl]-6-O-β-D-
glucopyranosyl-16-O-β-D-glucopyranosyl-3β,6α,16β,24(S)-25-
pentahydroxycycloartane (2)
Amorphous white solid; C52H88O23 [α]23D +15.0 (c 0.2 MeOH); IR
ν KBrmax cm−1: 3445 ( >OH), 2920 ( >CH); for 1H and 13C NMR
(Pyridine-d5, 400 MHz) data of the aglycone moiety and the sugar
portion see Tables 1 and 2, respectively; HRESIMS m/z 1103.5648 [M
+ Na]+ (calcd. for C52H88O23Na, 1103.5646) (positive mode). The
structure of compound 2 and key HMBCs (H→ C) is shown in Fig. 2.
3.4. Acid hydrolysis
The crude saponin mixture of fraction P (1 g) was heated at 60 °C
with 1:1 0.5 N HCl-dioxane (3 mL) for 2 h, and then evaporated in
vacuo. The solution was partitioned with EtOAc, and the H2O layer was
neutralized with 0.5 M NaOH. After gaining the hydrolysed mixture,
three monosaccharides were purified utilizing normal-phase silica gel
as stationary phase (35 × 120 mm, 55 g) eluting with CHCl3-MeOH-
H2O solvent system (95:5:0.5, 80:20:1, 80:20:2; 70:30:3; 61:32:7). After
purification, the obtained sugar units were identified by comparison
with authentic samples using TLC in CHCl3-MeOH-H2O (60:40:10)
system and their identity was confirmed after preparative TLC in the
same solvent. The optical rotation of each purified sugar was measured
to afford L-arabinose ([α]20D +70.0, c 0.1, H2O), D-xylose ([α]20D
+22.0, c 0.1, H2O) and D-glucose ([α]20D +13.0, c 0.1, H2O).
Table 2
13C and 1H NMR data (J in Hz) of the sugar portions of 1 and 2 (400 MHzfor 2, and 500
MHz for 1, δ ppm, in Pyridine-d5).
C/H 1 2
δC δH (J in Hz) δC δH (J in Hz)
β-D-Xyl (at C-
3)
β-D-Xyl (at C-3)
1 107.4 4.85, d (7.5) 105.4 4.86, d (6.8)
2 75.3 4.05, t (8.0) 83.5 4.12, t (7.6)
3 79.0 4.24, m 77.2 4.20, t (7.6)
4 71.6 4.14, m 71.0 4.19, m
5 66.7 4.35, dd (11.1, 5.0); 3.69, t
(10.6)
66.5 3.60, m
4.29, m
β-D-Glc (at C-6) α-L-Ara (at C-2 of Xyl)
1 105.1 4.89, d (7.7) 106.7 5.22, d (6.6)
2 75.4 4.00, dd (8.5, 7.5) 73.7 4.61, dd (7.2, 4.8)
3 78.2 4.24, t (9.0) 74.3 4.23, dd (7.2, 2.5)
4 71.0 4.23, t (9.6) 69.1 4.31, m
5 77.9 3.97, m 67.1 4.44, dd (12.0,
3.2);
3.82, d (11.4)
6 62.8 4.61, dd (11.0, 3.5);
4.36, m
– –
β-D-Glc (at C-16) β-D-Glc (at C-6)
1 106.3 4.73, d (7.7) 105.4 4.91, d (7.7)
2 75.4 4.00, dd (8.5, 7.5) 75.8 4.05, t (8.4)
3 78.2 4.15, t (9.0) 79.2 4.24, m
4 71.7 4.14, t (9.6) 72.1 4.16, t (7.6)
5 77.9 3.89, t (6.3) 78.0 3.97, t (7.6)
6 62.6 4.56, dd (11.0, 3.0);
4.35, dd (11.0, 5.0)
63.3 4.60, dd (7.6, 2.2);
4.37, m
β-D-Glc (at C-16)
1 106.6 4.75, d (7.6)
2 75.7 3.99, dd (7.6, 4.8)
3 78.6 4.17, t (6.8)
4 72.0 4.14, t (6.8)
5 78.2 3.90, m
6 62.9 4.55 dd (11.2,
1.6);
4.37, m
Table 3
Hemolytic activities of butanolic-, methanolic extracts and compounds 1, 1a and 2 from
A. brachycalyx a,b,c.
Group Absorbance value Hemolytic activity Hemolytic percentage
(%)
Saline 0.110 ± 0.0009 0.000 ± 0.002 0.00 ± 0.23
Distillated water 0.638 ± 0.004 1.00± 0.001 ** 100.03 ± 0.10**
AST VII (μg/mL)
5000 0.203± 0.0008 0.16 ± 0.01* 16.54 ± 1.89*
500 0.155 ± 0.002 0.085 ± 0.004 8.51 ± 0.43
250 0.124± 0.004 0.027 ± 0.0010 2.71 ± 0.10
125 0.123 ± 0.006 0.023 ± 0.0016 2.39 ± 0.16
50 0.121 ± 0.002 0.014 ± 0.005 1.47 ± 0.50
25 0.111 ± 0.005 0.014 ± 0.001 1.41 ± 0.12
12.5 0.111 ± 0.001 0.018 ± 0.002 0.18 ± 0.28
2.5 0.873 ± 0.002 −0.04 ± 0.004 −4.35 ± 0.47
QS-21 (μg/mL)
5000 2.573 ± 0.002 4.66 ± 0.005** 466 ± 0.50**
500 0.854 ± 0.009 1.65 ± 0.008 ** 165 ± 0.82**
250 0.873 ± 0.005 1.35± 0.001 ** 135 ± 1.34 **
125 0.984 ± 0.003 1.44 ± 0.002 ** 144 ± 0.21**
50 0.785 ± 0.003 1.40 ± 0.008 ** 140 ± 0.89**
25 0.514 ± 0.001 1.27± 0.02* 127.87 ± 2.41*
12.5 0.342 ± 0.005 0.76 ± 0.01* 76.58 ± 1.24*
2.5 0.155 ± 0.001 −0.08 ± 0.004* −8.880 ± 0.43*
Compound 1 (μg/mL)
5000 0.802 ± 0.000 1.30 ± 0.001*** 130.91 ± 1.18***
500 0.160 ± 0.004 0.09 ± 0.010* 9.38 ± 1.00*
250 0.156 ± 0.003 0.08 ± 0.008 8.63± 0.82
125 0.135 ± 0.001 0.047 ± 0.002 4.71 ± 0.28
50 0.131 ± 0.003 0.01 ± 0.007 1.88 ± 0.75
25 0.118 ± 0.004 0.015± 0.001 1.50 ± 0.10
12.5 0.116 ± 0.001 0.011 ± 0.003 1.12 ± 0.39
2.5 0.103 ± 0.003 −0.134 ± 0.007 −1.33 ± 0.78
Compound 1a (μg/mL)
5000 2.154 ± 0.001 3.84 ± 0.002** 384.98 ± 0.28**
500 0.152 ± 0.002 0.08 ± 0.004 8.01± 0.47
250 0.126 ± 0.002 0.030 ± 0.005 3.09 ± 0.54
125 0.126 ± 0.002 0.030 ± 0.005 3.09 ± 0.54
50 0.121 ± 0.002 0.02 ± 0.005 2.01 ± 0.50
25 0.111 ± 0.002 0.001 ± 0.006 0.12 ± 0.68
12.5 0.103 ± 0.003 −0.126 ± 0.008 −1.26 ± 0.89
2.5 0.103 ± 0.003 −0.013 ± 0.007 −1.32 ± 0.78
Compound 2 (μg/mL)
5000 0.194 ± 0.002 0.15 ± 0.006* 15.95 ± 0.66*
500 0.158 ± 0.003 0.09 ± 0.007 9.13 ± 0.78
250 0.148 ± 0.000 0.07 ± 0.001 7.18± 0.10
125 0.137 ± 0.009 0.05 ± 0.002 5.16± 0.21
50 0.118 ± 0.004 0.01 ± 0.009 1.51 ± 0.09
25 0.110 ± 0.008 −0.0008 ± 0.001 −0.75 ± 0.18
12.5 0.0733 ± 0.004 −0.07 ± 0.01 −7.01 ± 1.09
2.5 0.089 ± 0.001 −0.040 ± 0.006 −3.82 ± 0.61
δH (J in Hz)
5000 0.193 ± 0.003 0.15 ± 0.007* 15.76 ± 0.76*
500 0.133 ± 0.002 0.04 ± 0.006 4.27 ± 0.68
250 0.126 ± 0.001 0.03 ± 0.002 3.20 ± 0.21
125 0.118 ± 0.001 0.01 ± 0.003 1.43 ± 0.32
50 0.115 ± 0.008 0.008 ± 0.001 0.87 ± 0.18
25 0.109± 0.001 −0.002 ± 0.003 −0.26 ± 0.32
12.5 0.099 ± 0.004 −0.02 ± 0.001 −2.03 ± 0.10
2.5 0.089 ± 0.001 −0.04 ± 0.003 −4.05 ± 0.32
Butanol Extract (μg/mL)
5000 0.487 ± 0.008 0.68 ± 0.018** 71.41 ± 1.89**
500 0.142 ± 0.002 0.61 ± 0.004 6.10 ± 0.47
250 0.131 ± 0.002 0.03± 0.005 3.89 ± 0.50
125 0.122 ± 0.001 0.02 ± 0.003 2.19 ± 0.37
50 0.120 ± 0.009 0.01 ± 0.002 1.94 ± 0.21
25 0.102 ± 0.002 −0.01 ± 0.004 −1.46 ± 0.47
12.5 0.093 ± 0.004 −0.03± 0.001 −3.16 ± 0.10
2.5 0.088 ± 0.001 −0.04 ± 0.002 −4.11 ± 0.28
a *p< 0.05; **p< 0.01; ***p< 0.001.
b Hemolytic percents of saline and distilled water were included as minimal and
maximal hemolytic control.
c All values represent the mean ± standard deviation (n ¼ 3 test).
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3.5. Biological evaluation
3.5.1. Measurement of the effects on cytokine biosynthesis
Heparinized peripheral human whole blood from healthy volunteers
were stimulated with 50 ng PMA (Sigma, St. Lois, MO, U.S.A.) plus
400 ng ionomycin (Sigma, St. Lois, MO, U.S.A.) for IL-2, IFN-γ and IL-
17A and incubated in the presence of test samples or reference com-
pounds QS-21 and AST VII for 48 h. The cultured supernatants were
collected and the concentration of the cytokines produced by macro-
phages or lymphocytes were measured using a commercially available
enzyme-linked immunosorbent assay (ELISA) (eBioscience, Vienne,
Austria). The assays were performed according to the manufacturer’s
recommendations. The average absorbance readings of the samples
were then compared with the concentrations of the standard curve, and
the samples concentration of each cytokine was calculated. The results
of IL-2, IFN-γ and IL-17A were expressed as picograms per milliliter.
The minimum detection limits were 9.1 pg/mL, 0.99 pg/mL, and
0.5 pg/mL for IL-2, IFN-γ and IL-17A, respectively. Diluted super-
natants were used for all assays and each assay was performed in tri-
plicate.
3.5.2. Peripheral whole-blood cultures
Human whole blood (containing 20 U/mL heparine) was suspended
in RPMI-1640 medium supplemented with%10 FBS, 100 U/mL peni-
cillin and 100 mg/mL streptomycin in a 1:10 ratio. PMA (50 ng/mL)
and ionomycin (400 ng/mL) were added to the whole blood for sti-
mulation of immune system cells. The samples were dissolved as stock
solution in DMSO at concentration of 5 mg/mL and DMSO was used as
negative control. An amount of 1 mL of the heparinized blood which
was stimulated by PMA (50 ng/mL) and ionomycin (400 ng/mL) was
transferred into each well of 24-well plate and incubated at 37 °C for 48
in the absence or presence of 3 or 6 μg/mL concentrations of samples or
QS-21 and AST VII as reference compound. The diluted culture super-
natants were then mixed with sample dilent at 1:2 ratio and were as-
sayed using the specific ELISA method for IL-2, IFN-γ and IL-17A
(Lenarczyk et al., 2000; Nalbantsoy et al., 2011). The protocol was
approved by the Human Ethics Committee of Ege University, and all of
the used procedures conformed to the protocol was approved by the
Human Ethics Committee of Ege University, and all of the procedures
used conformed to the declaration of Helsinki. The subjects were in-
formed about the procedures and signed the informed consent forms
(approval number 15-11/19).
3.5.3. Hemolytic activity assay
Hemolytic activity of the molecules was measured according to
Nalbantsoy et al. (2011) with some modifications. Red blood cells ob-
tained from human healthy volunteers. Blood was collected with BD
Vacutainer TM (NH 143 I. U., Belliver Industrial Estate, Plymouth, UK).
An amount of 7 mL of blood was washed three times using sterile saline
solution (0.89%, w/v NaCl, pyrogen free) and then it was centrifuged at
2000 × g for 5 min. The final cell suspension was prepared by diluting
the pellet to 0.5% using saline solution. A volume of 0.01 mL of the cell
suspension was mixed in U button 96-well microplate with 0.05 mL
diluents containing 2.5, 12.5, 25, 50, 125, 250, 500 and 5000 μg/mL
concentrations of molecules in saline solutions. The mixtures were in-
cubated for 30 min at 37 °C and centrifuged at 800 × g for 10 min. The
free hemoglobin in the supernatants was measured spectro-
photometrically at 412 nm. Saline solution and distilled water were
used as minimal and maximal hemolytic controls. The hemolytic per-
cent developed by the saline control was subtracted from all groups.
Each experiment included triplicates at each concentration.
3.5.4. Statistical analysis
The data were expressed as mean ± standard deviation (S.D.) and
examined for their statistical significance of difference with Student t-
test, One-way ANOVA and the post hoc test Tamhane’s and dunnet
(depends on homogeneity and normality of the absorbance values)
using SPSS 16.0. P-values less than 0.05, 0.01 and 0.001 were con-
sidered to be statistically significant.
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